Category of Multiple Myeloma-Symptomatic Myeloma Posts on Medivizor
Navigation Menu

Category of Multiple Myeloma-Symptomatic Myeloma Posts on Medivizor

Looking for patients with newly diagnosed multiple myeloma to test a combination therapy

Posted by on Oct 31, 2019 in Multiple Myeloma | 0 comments

In a nutshell This study is evaluating the safety and effectiveness of the D-KRd regimen (daratumumab, carfilzomib, lenalidomide, and dexamethasone) in patients with multiple myeloma. The main outcome to be measured will be the number of patients who respond to treatment. This study is recruiting in Chicago, Illinois. The details Multiple myeloma (MM)...

Read More

Searching for patients to try combinations of treatments for newly diagnosed multiple myeloma.

Posted by on Jul 29, 2019 in Multiple Myeloma | 0 comments

In a nutshell This study is looking for patients with newly diagnosed multiple myeloma (MM) to try different treatment regimens. The main outcome that will be measured is the number of patients who do not experience cancer worsening after treatment. This trial is recruiting in Chicago, Illinois, United States. The details There are several...

Read More

Recommending bortezomib in multiple myeloma patients with poor kidney function

Recommending bortezomib in multiple myeloma patients with poor kidney function

Posted by on Aug 10, 2018 in Multiple Myeloma | 0 comments

In a nutshell This paper studied the effect of recommending bortezomib as the first drug to use for multiple myeloma in patients with poor kidney function. This study concluded that after bortezomib became the recommended drug, there was an increase in the number of patients who did not require dialysis. Some background Up to 50% of patients with...

Read More

Looking for participants with relapsed and/or refractory multiple myeloma to receive ixazomib or pomalidomide

Posted by on Feb 5, 2018 in Multiple Myeloma | 0 comments

In a nutshell This study aims to compare ixazomib plus dexamethasone versus pomalidomide plus dexamethasone on survival in participants with relapse and/or refractory multiple myeloma. The outcome to be measured is the duration of time until disease progresses (worsens).  The details Multiple myeloma is a cancer of the plasma cells in the...

Read More

Looking for untreated multiple myeloma patients to test a first-line combination chemotherapy with stem cell transplantation

Posted by on Sep 26, 2017 in Multiple Myeloma | 0 comments

In a nutshell This phase 2 clinical trial will test the effectiveness of a high-dose BeEAM chemotherapy as a first-line treatment for multiple myeloma. The primary outcome will be measured by the response to the treatment. The details BeEAM is a combination chemotherapy containing 4 different drugs (bendamustine, etoposide, cytarabine, and...

Read More

Looking for patients with relapsed or refractory multiple myeloma to test the safety and effectiveness of genetically engineered T-cells alone or with immunotherapy

Posted by on Sep 26, 2017 in Multiple Myeloma | 0 comments

In a nutshell This early phase 1 clinical trial will test the safety and effectiveness of genetically engineered NY-ESO-1 specific (c259) T-cells cells with or without pembrolizumab (Keytruda) in treating relapsed or refractory (unresponsive to treatment) multiple myeloma. The details NY-ESO-1 is a protein found on many types of cancer cells...

Read More

Looking for patients with multiple myeloma to test the effectiveness of a combination therapy post autologous stem cell transplantation

Posted by on Sep 2, 2017 in Multiple Myeloma | 0 comments

In a nutshell This phase 2 clinical trial will test the effectiveness of IRD, a combination therapy of ixazomib, lenalidomide, and dexamethasone, after stem cell transplantation, followed by ixazomib or lenalidomide as a maintenance therapy in treating multiple myeloma. The primary outcome will be measured by the disease improvement. The details...

Read More

Looking for patients with relapsed or refractory multiple myeloma to test the effectiveness of a combination chemotherapy prior to autologous stem cell transplantation

Posted by on Sep 2, 2017 in Multiple Myeloma | 0 comments

In a nutshell This phase 2 clinical trial will test the effectiveness of a combination of panobinostat (Farydak), gemcitabine (Gemzar), busulfan (Busulfex), and melphalan (Alkeran), and a stem cell transplant in treating multiple myeloma. The primary outcome will be measured by the time until the disease progresses. This trial is being conducted in...

Read More

Adding ixazomib to treatment improves outcomes for relapsed/refractory multiple myeloma

Adding ixazomib to treatment improves outcomes for relapsed/refractory multiple myeloma

Posted by on May 29, 2017 in Multiple Myeloma | 0 comments

In a nutshell This study examined the safety and effectiveness of ixazomib (Ninlaro) when added to the treatment of relapsed multiple myeloma. Researchers concluded that ixazomib was safe and effective at improving treatment outcomes for relapsed multiple myeloma. Some background The addition of biologic drugs to standard treatment regimens for...

Read More